Stocktoria
Lexaria Bioscience Corp. LEXX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2009-10-28
Lexaria Bioscience Corp. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 | $384,543 | $222,610 | $433,287 | $63,639 | $40,718 |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 | $215,415 | $199,717 | $408,102 | $33,889 | -$4,897 |
| R&D expense | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M | $387,074 | $555,730 | $492,864 | $54,185 | $9,024 |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | -$5.7M | — | — | — | — | -$1.3M |
| Interest expense | — | — | — | — | — | — | — | — | $6,015 | $2,250 |
| Income tax | — | — | — | $0 | $6,093 | $2,319 | $17,664 | $0 | $0 | $0 |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M | -$4.1M | $4.1M | $6.6M | -$1.9M | -$1.3M |
| EPS (diluted) | $-0.66 | $-0.47 | $-1.01 | — | — | — | — | — | — | — |
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M | -$2.6M | -$3.0M | -$2.5M | -$1.5M | -$660,856 |
| Free cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | — | -$2.6M | -$3.7M | — | -$1.5M | -$663,950 |
| Cash & equivalents | — | — | — | $5.8M | $10.9M | $1.3M | $1.3M | $1.7M | $2.5M | $93,409 |
| Inventory | — | — | $0 | $38,418 | $29,648 | $116,871 | $127,396 | $87,233 | $67,174 | $134,724 |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M | $2.8M | $2.7M | $2.4M | $2.9M | $566,638 |
| Total liabilities | $1.6M | $1.2M | $403,908 | $201,437 | $203,265 | $345,980 | $184,507 | $43,640 | $92,347 | $478,881 |
| Shareholders' equity | $3.0M | $8.0M | $3.0M | $7.9M | $13.1M | $2.5M | $2.5M | $2.4M | $2.8M | $266,045 |
Growth · year-over-year · Revenue CAGR 37.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +52.0% | +105.2% | -11.4% | -64.7% | +87.9% | +72.7% | -48.6% | +580.9% | +56.3% | — |
| Net income growth | — | — | — | — | — | -199.6% | -37.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-08-31. Facts plus Stocktoria's own computed scores — not investment advice.